{"id":39667,"date":"2025-08-19T17:33:30","date_gmt":"2025-08-19T09:33:30","guid":{"rendered":"https:\/\/flcube.com\/?p=39667"},"modified":"2025-08-19T17:33:30","modified_gmt":"2025-08-19T09:33:30","slug":"zhifei-biologicals-adult-and-adolescent-dtap-vaccine-gains-nmpa-trial-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39667","title":{"rendered":"Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval"},"content":{"rendered":"\n

Chongqing Zhifei Biological Co., Ltd. (SHE: 300122<\/a>), based in China, announced that its Acellular Pertussis, Diphtheria, and Tetanus (Component) Combined Vaccine for Adolescents and Adults has received the Notice of Acceptance for Drug Clinical Trial Application (Acceptance Number: CXSL2500705) from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of this new-generation vaccine.<\/p>\n\n\n\n

Vaccine Innovation<\/strong>
The Component DTaP Vaccine for Adolescents and Adults represents an advancement in vaccine technology. It is formulated by combining separately purified effective components of pertussis with those of diphtheria and tetanus, ensuring consistent vaccine quality. This formulation is designed for the prevention of pertussis, diphtheria, and tetanus in healthy individuals aged 7 years and above.<\/p>\n\n\n\n

Market Opportunity<\/strong>
Currently, there is no component DTaP vaccine for adolescents and adults approved for marketing in China. This acceptance by the NMPA paves the way for Chongqing Zhifei Biological to potentially introduce the first such vaccine in the country, addressing an unmet need in the market.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis,…<\/p>\n","protected":false},"author":1,"featured_media":39669,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,879,12,878],"class_list":["post-39667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-she-300122","tag-vaccine","tag-zhifei-biological"],"yoast_head":"\nZhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis, Diphtheria, and Tetanus (Component) Combined Vaccine for Adolescents and Adults has received the Notice of Acceptance for Drug Clinical Trial Application (Acceptance Number: CXSL2500705) from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of this new-generation vaccine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39667\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval\" \/>\n<meta property=\"og:description\" content=\"Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis, Diphtheria, and Tetanus (Component) Combined Vaccine for Adolescents and Adults has received the Notice of Acceptance for Drug Clinical Trial Application (Acceptance Number: CXSL2500705) from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of this new-generation vaccine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39667\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T09:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1911.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval\",\"datePublished\":\"2025-08-19T09:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667\"},\"wordCount\":177,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1911.webp\",\"keywords\":[\"Clinical trial results\",\"SHE: 300122\",\"Vaccine\",\"Zhifei Biological\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39667#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39667\",\"name\":\"Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1911.webp\",\"datePublished\":\"2025-08-19T09:33:30+00:00\",\"description\":\"Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis, Diphtheria, and Tetanus (Component) Combined Vaccine for Adolescents and Adults has received the Notice of Acceptance for Drug Clinical Trial Application (Acceptance Number: CXSL2500705) from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of this new-generation vaccine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39667\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1911.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1911.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39667#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval - Insight, China's Pharmaceutical Industry","description":"Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis, Diphtheria, and Tetanus (Component) Combined Vaccine for Adolescents and Adults has received the Notice of Acceptance for Drug Clinical Trial Application (Acceptance Number: CXSL2500705) from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of this new-generation vaccine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39667","og_locale":"en_US","og_type":"article","og_title":"Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval","og_description":"Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis, Diphtheria, and Tetanus (Component) Combined Vaccine for Adolescents and Adults has received the Notice of Acceptance for Drug Clinical Trial Application (Acceptance Number: CXSL2500705) from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of this new-generation vaccine.","og_url":"https:\/\/flcube.com\/?p=39667","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-19T09:33:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1911.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39667#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39667"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval","datePublished":"2025-08-19T09:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39667"},"wordCount":177,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39667#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1911.webp","keywords":["Clinical trial results","SHE: 300122","Vaccine","Zhifei Biological"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39667#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39667","url":"https:\/\/flcube.com\/?p=39667","name":"Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39667#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39667#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1911.webp","datePublished":"2025-08-19T09:33:30+00:00","description":"Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis, Diphtheria, and Tetanus (Component) Combined Vaccine for Adolescents and Adults has received the Notice of Acceptance for Drug Clinical Trial Application (Acceptance Number: CXSL2500705) from the National Medical Products Administration (NMPA). This marks a significant step forward in the development of this new-generation vaccine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39667#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39667"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39667#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1911.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1911.webp","width":1080,"height":608,"caption":"Zhifei Biological's Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39667#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1911.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39667"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39667\/revisions"}],"predecessor-version":[{"id":39670,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39667\/revisions\/39670"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39669"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}